BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...organoid models of ovarian cancer. Bayer AG, EOC Pharma Group, Kyowa Hakko Kirin Co. Ltd., NovaMedica LLC...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

...models of other rhabdomyosarcoma subtypes. Bayer AG, EOC Pharma Group, Kyowa Hakko Kirin Co. Ltd., NovaMedica LLC...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Neurology

...urea cycle disorder. Bayer AG , Eddingpharm Inc. , Kyowa Hakko Kirin Co. Ltd. , NovaMedica LLC...
BioCentury | Jul 13, 2015
Company News

Ferring, NovaMedica deal

...Ferring granted NovaMedica exclusive rights to commercialize its line of prescription drug products to treat inflammatory...
...to commercialize its line of prescription drug products to treat inflammatory bowel diseases in Russia. NovaMedica...
...and Pentasa mesalamine, which are controlled-release capsules of mesalamine, a cyclooxygenase (COX) inhibitor, for UC. NovaMedica...
BioCentury | Mar 31, 2014
Company News

NovaMedica, Societa Industria Farmaceutica Italiana S.p.A sales and marketing update

...Societa Industria Farmaceutica Italiana (SIFI) granted NovaMedica exclusive rights to commercialize eight ophthalmic products in the...
...inflammation and allergies; Octilia to treat irritation, reddening and pruritus; and vasoprotective agent Mirtilene Forte. NovaMedica...
...and the EU. NovaMedica declined to disclose details. SIFI could not be reached for comment. NovaMedica LLC...
BioCentury | Mar 31, 2014
Clinical News

Entinostat: Phase III start

...rights to develop and commercialize entinostat in China, Thailand, Taiwan and Malaysia. Syndax also granted NovaMedica...
...States (CIS) (see BioCentury, Sept. 9, 2013). Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Aromasin. NovaMedica LLC...
BioCentury | Mar 17, 2014
Company News

Ferrer, Venter Pharma S.L. deal

...and approved in Germany. Ferrer has commercialization rights to LacTest in Europe and Latin America. NovaMedica LLC...
...exclusive rights to develop and commercialize the product in the Commonwealth of Independent States (CIS). NovaMedica...
BioCentury | Feb 17, 2014
Clinical News

Entinostat: SPA received

...to develop and commercialize Syndax's entinostat in China, Thailand, Taiwan and Malaysia. Syndax also granted NovaMedica...
...York, N.Y.) markets Aromasin. Syndax Pharmaceuticals Inc. , Waltham, Mass. Eddingpharm Inc. , Shanghai, China NovaMedica LLC...
BioCentury | Feb 10, 2014
Company News

NovaMedica, Skolkovo Foundation biomanufacturing news

...R&D unit NovaMedica Innotech and not-for-profit Skolkovo will collaborate in building an R&D center for NovaMedica...
...on the campus of Skolkovo Technopark. The center is slated to start operations next year. NovaMedica...
...will finance equipment and installation. Skolkovo Technopark is a tax-free zone for R&D, according to NovaMedica...
BioCentury | Jan 27, 2014
Clinical News

Diclofenac regulatory update

...the U.S. under a 2009 deal (see BioCentury, June 22, 2009 & July 15, 2013). NovaMedica...
...2% in the Commonwealth of Independent States (CIS) for the indication (see BioCentury, Jan. 6). NovaMedica LLC...
Items per page:
1 - 10 of 18
BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...organoid models of ovarian cancer. Bayer AG, EOC Pharma Group, Kyowa Hakko Kirin Co. Ltd., NovaMedica LLC...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

...models of other rhabdomyosarcoma subtypes. Bayer AG, EOC Pharma Group, Kyowa Hakko Kirin Co. Ltd., NovaMedica LLC...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Neurology

...urea cycle disorder. Bayer AG , Eddingpharm Inc. , Kyowa Hakko Kirin Co. Ltd. , NovaMedica LLC...
BioCentury | Jul 13, 2015
Company News

Ferring, NovaMedica deal

...Ferring granted NovaMedica exclusive rights to commercialize its line of prescription drug products to treat inflammatory...
...to commercialize its line of prescription drug products to treat inflammatory bowel diseases in Russia. NovaMedica...
...and Pentasa mesalamine, which are controlled-release capsules of mesalamine, a cyclooxygenase (COX) inhibitor, for UC. NovaMedica...
BioCentury | Mar 31, 2014
Company News

NovaMedica, Societa Industria Farmaceutica Italiana S.p.A sales and marketing update

...Societa Industria Farmaceutica Italiana (SIFI) granted NovaMedica exclusive rights to commercialize eight ophthalmic products in the...
...inflammation and allergies; Octilia to treat irritation, reddening and pruritus; and vasoprotective agent Mirtilene Forte. NovaMedica...
...and the EU. NovaMedica declined to disclose details. SIFI could not be reached for comment. NovaMedica LLC...
BioCentury | Mar 31, 2014
Clinical News

Entinostat: Phase III start

...rights to develop and commercialize entinostat in China, Thailand, Taiwan and Malaysia. Syndax also granted NovaMedica...
...States (CIS) (see BioCentury, Sept. 9, 2013). Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Aromasin. NovaMedica LLC...
BioCentury | Mar 17, 2014
Company News

Ferrer, Venter Pharma S.L. deal

...and approved in Germany. Ferrer has commercialization rights to LacTest in Europe and Latin America. NovaMedica LLC...
...exclusive rights to develop and commercialize the product in the Commonwealth of Independent States (CIS). NovaMedica...
BioCentury | Feb 17, 2014
Clinical News

Entinostat: SPA received

...to develop and commercialize Syndax's entinostat in China, Thailand, Taiwan and Malaysia. Syndax also granted NovaMedica...
...York, N.Y.) markets Aromasin. Syndax Pharmaceuticals Inc. , Waltham, Mass. Eddingpharm Inc. , Shanghai, China NovaMedica LLC...
BioCentury | Feb 10, 2014
Company News

NovaMedica, Skolkovo Foundation biomanufacturing news

...R&D unit NovaMedica Innotech and not-for-profit Skolkovo will collaborate in building an R&D center for NovaMedica...
...on the campus of Skolkovo Technopark. The center is slated to start operations next year. NovaMedica...
...will finance equipment and installation. Skolkovo Technopark is a tax-free zone for R&D, according to NovaMedica...
BioCentury | Jan 27, 2014
Clinical News

Diclofenac regulatory update

...the U.S. under a 2009 deal (see BioCentury, June 22, 2009 & July 15, 2013). NovaMedica...
...2% in the Commonwealth of Independent States (CIS) for the indication (see BioCentury, Jan. 6). NovaMedica LLC...
Items per page:
1 - 10 of 18